Beech Biotech SA Secures $1.9M to Revolutionize Preeclampsia Treatment with “Mother Only” Monoclonals

Beech Biotech SA, an innovative leader in the biotechnology arena, has successfully raised €1,900,000 in its latest funding round—a critical milestone that underscores investor confidence in the company’s groundbreaking approach to maternal health. Specializing in unlocking novel biology, Beech Biotech is focused on developing breakthrough treatments for preeclampsia and other complications of pregnancy, conditions that tragically affect millions worldwide. Preeclampsia alone claims the lives of approximately 70,000 mothers and 500,000 babies annually, while leaving 300 million survivors to grapple with long-term health repercussions. In response to these staggering figures, the company is pioneering a new class of “Mother only” monoclonal therapies engineered to treat the mother without exposing the fetus to unnecessary risks. The recent infusion of capital will accelerate the development of their lead asset, MOm303, a monoclonal antibody designed to bind and eliminate maternal sFlt-1—a key agent responsible for vascular deterioration in preeclampsia. By neutralizing sFlt-1, MOm303 helps restore the balance of placental growth factor, potentially prolonging pregnancy and mitigating the severe consequences associated with preterm birth. With its patented modification that prevents antibodies from crossing the placenta, Beech Biotech is addressing an unmet need in maternal-fetal medicine, paving the way for safer and more effective treatments. This funding milestone not only fuels the company’s research and development efforts but also marks a promising step toward transforming the standard of care for pregnant women and their unborn children around the globe.